#USA #New York #Securities Class Action #deramiocel #Capricor Therapeutics

The Gross Law Firm's Class Action for Capricor Therapeutics Shareholders

On August 14, 2025, the Gross Law Firm announced the initiation of a securities class action on behalf of shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). The law firm is urging investors who purchased shares during the specified period—October 9, 2024, to July 10, 2025—to reach out for potential lead plaintiff appointments. It's essential to note that being appointed as a lead plaintiff is not a prerequisite for participating in any recovery.

Background on Capricor Therapeutics

Capricor Therapeutics specializes in innovative therapies for rare diseases, with its lead candidate being deramiocel. This drug aims to treat cardiomyopathy, a serious condition associated with Duchenne muscular dystrophy (DMD). Investors were optimistic about Capricor's promising statements regarding the drug's potential approval and its impact on the market, particularly after announcements about pursuing a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA).

However, the situation turned critical when, on July 11, 2025, Capricor disclosed that it had received a Complete Response Letter (CRL) from the FDA. The letter stated that the company’s BLA did not meet the statutory requirements for substantial effectiveness evidence and highlighted the need for additional clinical data. This revelation was a significant blow to investors who had been led to believe in the drug’s positive trajectory based on prior communications from Capricor’s management.

Impact on Stock Prices

Following the FDA’s disclosure, the price of Capricor's stock saw a dramatic decline, plummeting from $11.40 per share on July 10 to $7.64 the following day. This sharp decline raised alarms among investors, many of whom felt misled by the information provided prior to the announcement. The Gross Law Firm is seeking to protect the rights of these investors who may have financially suffered due to misleading statements made by the company.

How to Participate

Shareholders interested in joining this class action are encouraged to visit the Gross Law Firm’s website and fill out a form related to the case. The firm offers portfolio monitoring services to keep participants updated on the case's developments throughout its lifecycle. It's crucial for investors to register before the deadline—September 15, 2025—to ensure their involvement and have a chance at recovery.

Why Choose Gross Law Firm?

The Gross Law Firm is a well-regarded class action law firm dedicated to safeguarding investors' rights in the face of deceit and unethical business practices. Their commitment extends to holding companies accountable for misrepresentations and ensuring fair treatment for all affected parties. With a track record of tackling complex securities cases, they ensure thorough representation for their clients.

In conclusion, if you are a shareholder of Capricor Therapeutics and purchased shares within the defined period, it’s advisable to act promptly to register with the Gross Law Firm. Your participation could play a vital role in seeking justice for losses incurred due to misleading corporate communication. The Gross Law Firm stands ready to assist investors in navigating this litigation process, helping to recover losses tied to stock price influences derived from corporate misrepresentations.